MORRIS PLAINS, N.J., Jan. 29, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a single amino acid change in the binding region of veltuzumab improved its potency in preclinical lymphoma models. Results from this study were published by D.M. Goldenberg, E.A. Rossi, R. Stein, T.M. Cardillo, M.S. Czuczman, F.J. Hernandez-Ilizaliturri, H.J. Hansen and C-H. Chang in a paper entitled "Property and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody," in the January 29, 2009, issue of Blood. This study was supported in part by a grant from the National Cancer Institute.
